UKCA Clinical Evaluation: What EU MDR Experts Miss

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

I review clinical evaluation reports prepared for both EU and UK markets regularly. The pattern is consistent. Teams duplicate their EU MDR CER, swap references to the European Commission with MHRA, and expect the file to pass.

It does not.

The problem is not that UK MDR diverges dramatically from EU MDR. The problem is that the differences are subtle enough to be overlooked but significant enough to cause non-conformities during assessment. Approved Bodies know where to look. And when they find misalignment, they do not accept EU-centric justifications.

The Foundational Difference: Two Regulatory Regimes

UK MDR is based on the original EU MDR 2017/745 as it stood before the UK left the European Union. Since that date, the UK and EU regulatory frameworks have evolved independently.

For clinical evaluation, this means several things:

First, MDCG guidance documents are not automatically applicable in the UK. The MHRA may adopt equivalent guidance, modify it, or issue entirely separate expectations. You cannot cite MDCG 2020-13 in a UK submission without verifying that MHRA has recognized or aligned with its content.

Second, the Approved Bodies operating under UKCA are not the same entities as EU Notified Bodies. They have been designated under UK rules, and their assessment practices reflect MHRA oversight, not European Commission oversight.

Third, references to harmonized standards must be checked against the UK standards list maintained by MHRA. A standard harmonized under the EU system is not automatically valid for UKCA unless explicitly recognized in the UK.

Clinical Data Requirements: Same Core, Different References

The requirement to demonstrate safety and performance through clinical data remains identical in principle. Annex XIV of UK MDR is structurally the same as Annex XIV of EU MDR.

But implementation details differ.

In the EU, clinical evaluation relies heavily on MDCG guidance for interpreting Annex XIV. MDCG 2020-5 on clinical evaluation, MDCG 2020-6 on sufficient clinical evidence, and MDCG 2020-13 on clinical evaluation for legacy devices form the interpretive framework.

In the UK, MHRA has issued its own guidance on clinical investigations and post-market clinical follow-up. Where MHRA has not provided specific guidance, Approved Bodies tend to apply their interpretation of UK MDR directly, sometimes informed by pre-Brexit MEDDEV documents or internal assessment protocols.

This creates a gap. If your CER was written to satisfy MDCG 2020-5, and the Approved Body is assessing against MHRA guidance that diverges on a specific point, you will receive a deficiency notice even though your EU file was accepted without question.

The most common area where this surfaces is equivalence demonstration.

Equivalence Under UKCA: Not Identical to EU Practice

Equivalence is already one of the most contested areas in clinical evaluation. Under EU MDR, MDCG 2020-5 provides detailed requirements for demonstrating technical, biological, and clinical equivalence.

UK MDR does not reference MDCG 2020-5.

Approved Bodies working under UKCA may accept an equivalence claim structured according to MDCG 2020-5 if it is robust. But they are not required to follow MDCG interpretations. Some Approved Bodies apply stricter criteria for technical equivalence. Others request additional justification for clinical equivalence where MDCG 2020-5 might have been sufficient in the EU.

I have seen equivalence claims accepted by an EU Notified Body and then questioned by a UK Approved Body on the basis that the technical comparison did not sufficiently address differences in materials or manufacturing tolerages. The data was the same. The interpretation of sufficiency was not.

This is not because UK Approved Bodies are being difficult. It is because they are operating in a regulatory environment where MDCG guidance does not have formal status, and they are expected to exercise independent judgment based on UK MDR text and MHRA expectations.

State of the Art: Same Concept, Different Literature Base

Demonstrating that your device reflects the current state of the art is required under both EU MDR and UK MDR. Annex I, Chapter I, Section 1 of both regulations includes the same language.

But the literature base you search and the standards you reference may differ.

In the EU, state of the art evaluation often relies on harmonized standards listed in the Official Journal of the European Union. These standards are presumed to confer conformity with the relevant essential requirements.

In the UK, MHRA maintains its own list of recognized standards. This list is not identical to the EU list, especially for standards published or updated after the end of the transition period.

If your SOTA section cites a standard that is harmonized in the EU but not recognized in the UK, the Approved Body may request alternative evidence that you meet the relevant essential requirement.

This does not happen often, but when it does, it delays certification because you must either locate a UK-recognized alternative standard or provide direct evidence of conformity without relying on the standard.

The same issue applies to clinical literature. If your SOTA search relied on databases or journals that are primarily EU-focused, and the Approved Body identifies relevant UK-based studies or guidelines that were not included, they will ask why those were excluded.

Post-Market Clinical Follow-Up: MHRA Expectations

PMCF is mandatory under both EU MDR and UK MDR. The requirement to generate post-market clinical data and update the clinical evaluation throughout the lifecycle is identical.

Where differences emerge is in how MHRA expects PMCF to be planned and reported.

In the EU, MDCG 2020-7 and MDCG 2020-8 provide detailed guidance on PMCF plans and PMCF evaluation reports. EU Notified Bodies assess PMCF documentation against these templates.

In the UK, MHRA has issued separate guidance on post-market surveillance, but it does not mirror MDCG 2020-7 and 2020-8 exactly. Approved Bodies are aware of the MDCG documents but are not bound by them.

I have reviewed PMCF plans that were accepted in the EU but flagged in the UK for insufficient detail on how adverse events would trigger re-evaluation of clinical data. The plan structure was based on MDCG 2020-7. The Approved Body wanted more explicit linkage to MHRA vigilance reporting requirements.

If your PMCF plan mentions EUDAMED, Approved Bodies will ask how that data will be accessed or what UK-equivalent system you will use. If your periodic safety update report follows the EU format but does not align with MHRA reporting cycles, they will request adjustment.

Notified Body vs Approved Body: Different Oversight Cultures

This is the difference manufacturers feel but cannot always articulate.

EU Notified Bodies operate under the oversight of national competent authorities and coordination by the European Commission. Their interpretation of MDR is influenced by MDCG guidance, joint assessments, and peer review mechanisms.

UK Approved Bodies operate under MHRA oversight alone. There is no UK equivalent to MDCG. There is no joint assessment process across multiple Approved Bodies.

This means that each UK Approved Body develops its own assessment culture based on MHRA expectations and internal protocols. There is less harmonization across Approved Bodies in the UK than across Notified Bodies in the EU.

If you switch Approved Bodies, you may encounter different expectations even though the regulation is the same. This is not a flaw in the system. It is a consequence of a smaller, more independent regulatory structure.

The practical implication for clinical evaluation is that you cannot assume that practices accepted by one Approved Body will be automatically accepted by another. You must engage early and confirm expectations before finalizing the CER.

Northern Ireland: A Third Regulatory Path

Northern Ireland adds another layer of complexity.

Medical devices placed on the Northern Ireland market must comply with EU MDR, not UK MDR. This is a consequence of the Northern Ireland Protocol.

If you are manufacturing in Great Britain (England, Scotland, Wales) but placing devices in Northern Ireland, you need both UKCA certification and CE marking under EU MDR.

Your clinical evaluation report must therefore satisfy both regimes. You cannot write one CER that works for both unless you address both sets of regulatory expectations explicitly.

Most manufacturers handle this by maintaining two versions of the CER: one aligned with MDCG guidance for EU and Northern Ireland, and one adapted for UK MDR and Approved Body expectations.

This is not duplication. It is recognition that the regulatory frameworks have diverged, and compliance requires deliberate adaptation.

What This Means for Your Clinical Evaluation Strategy

If you are preparing a clinical evaluation report for UKCA certification, you cannot treat it as a copy-paste exercise from your EU file.

You must verify that every reference to guidance, every citation of standards, and every assumption about regulatory expectations aligns with UK MDR and MHRA oversight.

You must engage your Approved Body early to confirm their interpretation of equivalence, state of the art, and PMCF requirements.

You must separate your EU and UK documentation where the regulatory paths diverge, and you must maintain both pathways if you are placing devices in both markets.

The manufacturers who struggle with UKCA certification are those who assume that EU compliance guarantees UK compliance. It does not.

The manufacturers who achieve certification efficiently are those who treat UK MDR as a distinct regulatory regime with its own logic, expectations, and oversight culture.

Your clinical evaluation report must reflect that distinction. Not just in the title page, but in every section where regulatory alignment matters.

If you are working on both markets simultaneously, the regulatory burden is real. You are navigating two parallel systems that share a common origin but no longer share a common path.

This is the reality post-Brexit. The question is whether your clinical evaluation process has adapted to it.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.